JP2004500125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500125A5 JP2004500125A5 JP2002504285A JP2002504285A JP2004500125A5 JP 2004500125 A5 JP2004500125 A5 JP 2004500125A5 JP 2002504285 A JP2002504285 A JP 2002504285A JP 2002504285 A JP2002504285 A JP 2002504285A JP 2004500125 A5 JP2004500125 A5 JP 2004500125A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- compound
- cells
- gpcrx11
- unknown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 18
- 108010021336 lanreotide Proteins 0.000 claims description 18
- 229960002437 lanreotide Drugs 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims 79
- 108020003175 receptors Proteins 0.000 claims 79
- 210000004027 cell Anatomy 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 60
- 238000000034 method Methods 0.000 claims 47
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 102000005157 Somatostatin Human genes 0.000 claims 17
- 108010056088 Somatostatin Proteins 0.000 claims 17
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 17
- 229960000553 somatostatin Drugs 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 11
- 229940125425 inverse agonist Drugs 0.000 claims 11
- 238000012216 screening Methods 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 9
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 claims 8
- 238000005406 washing Methods 0.000 claims 8
- 238000012258 culturing Methods 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 5
- 231100000673 dose–response relationship Toxicity 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000008569 process Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004020 luminiscence type Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000013641 positive control Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000010200 validation analysis Methods 0.000 claims 2
- 108010000239 Aequorin Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 108010041089 apoaequorin Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000037011 constitutive activity Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000003572 second messenger assay Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21291300P | 2000-06-20 | 2000-06-20 | |
| US21749400P | 2000-07-11 | 2000-07-11 | |
| EP01870015 | 2001-01-26 | ||
| EP01870024 | 2001-02-12 | ||
| PCT/BE2001/000104 WO2001098330A2 (en) | 2000-06-20 | 2001-06-20 | A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500125A JP2004500125A (ja) | 2004-01-08 |
| JP2004500125A5 true JP2004500125A5 (enExample) | 2005-02-24 |
Family
ID=56290152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504285A Pending JP2004500125A (ja) | 2000-06-20 | 2001-06-20 | アンギオペプチンによって確認される機能性受容体としてのＧＰＣＲｘ１１を発現し、アゴニストおよびアンタゴニストのスクリーニングに役立つ組換え細胞系 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1297003A2 (enExample) |
| JP (1) | JP2004500125A (enExample) |
| AU (1) | AU2001265717A1 (enExample) |
| CA (1) | CA2413435A1 (enExample) |
| WO (1) | WO2001098330A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020119493A1 (en) * | 2000-07-21 | 2002-08-29 | Glucksmann Maria Alexandra | 65494, a novel human G-protein-coupled receptor family member and uses thereof |
| GB2367297A (en) * | 2000-07-07 | 2002-04-03 | Smithkline Beecham Corp | AXOR95 polypeptides and polynucleotides |
| EP1379656A2 (en) * | 2001-02-14 | 2004-01-14 | Amgen Inc. | G-protein coupled receptor molecules and uses thereof |
| EP1382678B1 (en) * | 2001-04-25 | 2008-08-27 | Astellas Pharma Inc. | Guanosine triphosphate-binding protein-coupled recepotr place 6002312 and its gene and production and use of the same |
| WO2003027142A1 (fr) * | 2001-09-21 | 2003-04-03 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau recepteur couple a la proteine g |
| WO2003046147A2 (en) * | 2001-11-26 | 2003-06-05 | Bristol-Myers Squibb Company | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof |
| EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
| DE10225443A1 (de) * | 2002-06-08 | 2003-12-18 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Agonisten oder Antagonisten für den G-Protein gekoppelten Rezeptor mas like 1 |
| AU2003276136A1 (en) * | 2002-11-04 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
| US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
| WO2004048978A2 (en) * | 2002-11-22 | 2004-06-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
| EP1644513B1 (en) * | 2003-06-20 | 2011-08-10 | DiscoveRx Corporation | Assay for detecting protein binding |
| WO2008063321A2 (en) | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
| CN116410335B (zh) * | 2023-04-24 | 2024-08-13 | 徐州医科大学 | 一种多肽tat-mrgprx1c及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704836D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Pharma Inc | Novel receptor |
| WO2001016159A1 (en) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, theant |
| IL148515A0 (en) * | 1999-09-16 | 2002-09-12 | Solvay Pharm Bv | Human g-protein coupled receptor |
| WO2001036473A2 (en) * | 1999-11-16 | 2001-05-25 | Pharmacia & Upjohn Company | Human g protein-coupled receptors |
| CN1310945C (zh) * | 1999-11-17 | 2007-04-18 | 阿瑞那制药公司 | 人g蛋白偶联受体的内源形式和非内源形式 |
| WO2001048189A1 (fr) * | 1999-12-28 | 2001-07-05 | Helix Research Institute | Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers |
| EP1242454A2 (en) * | 1999-12-28 | 2002-09-25 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
-
2001
- 2001-06-20 AU AU2001265717A patent/AU2001265717A1/en not_active Abandoned
- 2001-06-20 EP EP01942923A patent/EP1297003A2/en not_active Withdrawn
- 2001-06-20 JP JP2002504285A patent/JP2004500125A/ja active Pending
- 2001-06-20 WO PCT/BE2001/000104 patent/WO2001098330A2/en not_active Ceased
- 2001-06-20 CA CA002413435A patent/CA2413435A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500125A5 (enExample) | ||
| KR20010102507A (ko) | 용도 | |
| JPH10262687A (ja) | 新規ヒト１１ｃｂスプライス変種 | |
| WO2000024890A1 (en) | Novel g protein-coupled receptor proteins, dnas thereof and ligands to the same | |
| JPH10327888A (ja) | 新規ｇ−タンパク質結合レセプター（ｈｆｇａｎ７２ｘ） | |
| JPH10327889A (ja) | 新規ｇ−タンパク質結合レセプター（ｈｆｇａｎ７２ｙ） | |
| JP2002515233A (ja) | ヒトＥＤＧ３ｓｂ遺伝子 | |
| JP2004500125A (ja) | アンギオペプチンによって確認される機能性受容体としてのＧＰＣＲｘ１１を発現し、アゴニストおよびアンタゴニストのスクリーニングに役立つ組換え細胞系 | |
| JP2000083669A (ja) | Ｃｘｃｒ４ケモカイン受容体のヒトスプライス変異体ｃｘｃｒ４ｂ | |
| CA2239605A1 (en) | Novel g-protein coupled receptor (h7tba62) | |
| US20070117138A1 (en) | Splice variant cannabinoid receptor (cb1b) | |
| JP2002517222A (ja) | Ｇｐｒ３５ａ受容体 | |
| JPH1175870A (ja) | 新規なヒトｇ−タンパク質結合レセプター（ｈｃｅｐｔ０９） | |
| AU771950B2 (en) | Compositions corresponding to a calcium transporter and methods of making and using same | |
| JP2002512780A (ja) | 新規７ｔｍ受容体ａｘｏｒ−２のクローニング | |
| JP2002508934A (ja) | Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド | |
| JPH1118788A (ja) | Ｇタンパク質共役受容体 ｈｏｆｎｈ３０ | |
| US20030059856A1 (en) | Methods of screening for agonists and agonists of the interaction between the AXOR8 and AXOR52 receptors and ligands thereof | |
| US7696339B2 (en) | Nucleic acid encoding monkey QRFP | |
| JP2002512016A (ja) | Ｅｄｇファミリー遺伝子、ヒトｈ２１８ | |
| JP2002520041A (ja) | Ｇタンパク質共役受容体ａｘｏｒ１０ | |
| US6441133B1 (en) | Thyrotropin-releasing hormone receptor 2(TRHR-2) | |
| JPH1175866A (ja) | マウスＦｒｉｚｚｌｅｄ−６ 遺伝子に類似したヒト７ＴＭ受容体 | |
| JP2009079033A (ja) | 骨芽細胞分化誘導因子遺伝子及びその利用 | |
| JP2002511388A (ja) | ヒトｇタンパク質共役受容体（ｇｐｒ２５） |